Prostate cancer cures lay in the various forms of treatments available as therapy for the disease.Common Treatments for Prostate CancerRadiation, hormone therapy, radical prostatecomy, chemotherapy, and cryotherapy, which seeks to destroy cancer cells by freezing them...

Prostate cancer medications working in conjunction with hormonal therapy serve as an aggressive treatment against the progression of prostate cancer. Wonder why? Well, man produce a hormone commonly known as testosterone, often equated with making a guy "macho," testo...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48503) has announced the addition of Zurich: UK Personal General Insurance Competitor Profile 2006 to their offering. This profile provides an overview of Zurichs UK personal general...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48485) has announced the addition of Next Generation Network OSS OSS - Office of Strategic ServicesOSS - Open Source SoftwareOSS - Advanced Broadband Operational Support SystemsOSS - ...

Byline: Jason Z. Cohen Staff Writer THOUSAND OAKS - Amgen Inc. presented promising new data from trials of its prostate cancer drug to doctors attending the American Society of Clinical Oncology on Tuesday. The company has completed Phase III clinical trials for Ab...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 10, 1999--Amgen (NASDAQ:AMGN) today announced that it has entered into a collaboration with PRAECIS PHARMACEUTICALS INCORPORATED under which the companies will develop and Amgen will commercialize abarelix in the United S...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48492) has announced the addition of Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the Unite...

Business Editors/Health/Medical Writers WALTHAM, Mass.--(BUSINESS WIRE)--May 31, 2003 PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS PRCS - Palestine Red Crescent SocietyPRCS - Permit Required Confined SpacePRCS - Primary Reaction Control SystemPRCS - Pseudoran...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48450) has announced the addition of the new Bioseeker report "Prostate Cancer: Drug Pipeline Update 2007" to their offering. Cancer of the prostate is the second most frequently dia...

Business EditorsTHOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 25, 2000Amgen (Nasdaq:AMGN) today announced that earnings per share for the first quarter ended March 31, 2000 increased 9 percent, to $0.25 from $0.23 for the first quarter of 1999. Net income increased ...

Business Editors/Health/Medical Writers WALTHAM, Mass.--(BUSINESS WIRE)--March 12, 2003 PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced the presentation of results from ABACAS 1, a phase 3 clinical study of Plenaxis(TM) (abarelix for injectable ...

Business Editors/Health/Medical Writers WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 26, 2003 PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS PRCS - Palestine Red Crescent SocietyPRCS - Permit Required Confined SpacePRCS - Primary Reaction Control SystemPRCS - Pseudora...

A new class of prostate cancer drug could offer hope for thousands of men who are diagnosed with prostate cancer every year. In the US alone, an estimated 180,000 men will be diagnosed with prostate cancer and 32,000 men will die this year as a result of the dis...

Amgen (One Amgen Center Dr., Thousand Oaks, CA 91320; Tel: 805/447-1000, Fax: 805/447-1010, Website: www.amgen.com) and Praecis Pharmaceuticals, Inc. (Cambridge, MA, Contact: Susan Schumacher, 617/587-2921) will collaborate on the commercialization of abarelix, a GnR...

You've got to be selective, but the insider profile remains generally positive in biotech, especially among the smaller, more speculative names. At cardio-device maker Thoratec Corp. (THOR), Director William Hitchcock picked up more than 20,000 shares at $8 to $9 in l...

WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today provided an update on the Company's commercialization of Plenaxis(R) (abarelix for injectable suspension) in the United States. The Company stated that Plenaxis(R) is an important therapy for...

Men with advanced cases of prostate cancer now have an additional treatment option. In November 2003, the FDA approved Plenaxis (abarelix), a drug given as an injection. Plenaxis lowers the male hormone testosterone, a key factor involved in most prostate cancer growt...

WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ:PRCS), today announced that it will report third quarter 2004 financial results on Friday, October 29, 2004, before the financial markets open. The release will be followed by a conference call with the in...

WALTHAM, Mass. -- Dr. Gefter Will Remain as Chairman and Serve as Chief Scientific Officer ...

Prostate cancer cures lay in the various forms of treatments available as therapy for the disease.Common Treatments for Prostate CancerRadiation, hormone therapy, radical prostatecomy, chemotherapy, and cryotherapy, which seeks to destroy cancer cells by freezing them...

Prostate cancer medications working in conjunction with hormonal therapy serve as an aggressive treatment against the progression of prostate cancer. Wonder why? Well, man produce a hormone commonly known as testosterone, often equated with making a guy "macho," testo...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48503) has announced the addition of Zurich: UK Personal General Insurance Competitor Profile 2006 to their offering. This profile provides an overview of Zurichs UK personal general...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48485) has announced the addition of Next Generation Network OSS OSS - Office of Strategic ServicesOSS - Open Source SoftwareOSS - Advanced Broadband Operational Support SystemsOSS - ...

Byline: Jason Z. Cohen Staff Writer THOUSAND OAKS - Amgen Inc. presented promising new data from trials of its prostate cancer drug to doctors attending the American Society of Clinical Oncology on Tuesday. The company has completed Phase III clinical trials for Ab...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 10, 1999--Amgen (NASDAQ:AMGN) today announced that it has entered into a collaboration with PRAECIS PHARMACEUTICALS INCORPORATED under which the companies will develop and Amgen will commercialize abarelix in the United S...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48492) has announced the addition of Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the Unite...

Business Editors/Health/Medical Writers WALTHAM, Mass.--(BUSINESS WIRE)--May 31, 2003 PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS PRCS - Palestine Red Crescent SocietyPRCS - Permit Required Confined SpacePRCS - Primary Reaction Control SystemPRCS - Pseudoran...

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c48450) has announced the addition of the new Bioseeker report "Prostate Cancer: Drug Pipeline Update 2007" to their offering. Cancer of the prostate is the second most frequently dia...

Business EditorsTHOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 25, 2000Amgen (Nasdaq:AMGN) today announced that earnings per share for the first quarter ended March 31, 2000 increased 9 percent, to $0.25 from $0.23 for the first quarter of 1999. Net income increased ...

Business Editors/Health/Medical Writers WALTHAM, Mass.--(BUSINESS WIRE)--March 12, 2003 PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced the presentation of results from ABACAS 1, a phase 3 clinical study of Plenaxis(TM) (abarelix for injectable ...

Business Editors/Health/Medical Writers WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 26, 2003 PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS PRCS - Palestine Red Crescent SocietyPRCS - Permit Required Confined SpacePRCS - Primary Reaction Control SystemPRCS - Pseudora...

A new class of prostate cancer drug could offer hope for thousands of men who are diagnosed with prostate cancer every year. In the US alone, an estimated 180,000 men will be diagnosed with prostate cancer and 32,000 men will die this year as a result of the dis...

Amgen (One Amgen Center Dr., Thousand Oaks, CA 91320; Tel: 805/447-1000, Fax: 805/447-1010, Website: www.amgen.com) and Praecis Pharmaceuticals, Inc. (Cambridge, MA, Contact: Susan Schumacher, 617/587-2921) will collaborate on the commercialization of abarelix, a GnR...

You've got to be selective, but the insider profile remains generally positive in biotech, especially among the smaller, more speculative names. At cardio-device maker Thoratec Corp. (THOR), Director William Hitchcock picked up more than 20,000 shares at $8 to $9 in l...

WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today provided an update on the Company's commercialization of Plenaxis(R) (abarelix for injectable suspension) in the United States. The Company stated that Plenaxis(R) is an important therapy for...

Men with advanced cases of prostate cancer now have an additional treatment option. In November 2003, the FDA approved Plenaxis (abarelix), a drug given as an injection. Plenaxis lowers the male hormone testosterone, a key factor involved in most prostate cancer growt...

WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ:PRCS), today announced that it will report third quarter 2004 financial results on Friday, October 29, 2004, before the financial markets open. The release will be followed by a conference call with the in...

WALTHAM, Mass. -- Dr. Gefter Will Remain as Chairman and Serve as Chief Scientific Officer ...